4 ms·
It's an interesting industry that needs billions to bring a new drug to market. At the same time it creates a lot of value to a patient. But the manufacturing o
by zurfer 9mo ago
It's an interesting industry that needs billions to bring a new drug to market. At the same time it creates a lot of value to a patient. But the manufacturing of a single dose is usually tiny.
Now how do you price that? The profits here will reward pharma investors and enable more investments in RnD of new medicines. I feel that's mostly fair.
- Scene_Cast2 9mo agoSome types of software aren't too far from that paradigm.
- kingstnap 9mo agoThe typical other solution for this is government grants for research. It could work but there are problems in (1) the amount of money required and (2) the funding research -> getting votes pipeline is borked (credit assignment in general is borked).
- AvocadoPanic 9mo agoThe 'risk' here is often carried by publicly funded research. ~6.2 billion for glp The private 'investment' comes in manufacturing, scale and marketing. Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years.
- 15155 9mo ago> Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years. So they are good stewards of their funds and know they can't deploy as much as they have? Berkshire Hathaway does the same thing.
- AvocadoPanic 9mo agoIs Berkshire Hathaway able to monitize the output of government funded research as effectively?
- deleted 9mo ago[deleted]